Medicinova (MNOV) Non-Current Assets (2010 - 2026)
Medicinova (MNOV) posted quarterly Non-Current Assets of $14.6 million for Q4 2025, down 1.28% year-over-year from $14.8 million in Q4 2024, and little changed quarter-over-quarter from $14.7 million in Q3 2025.
Medicinova (MNOV) Non-Current Assets (2010 - 2026) Analysis & Trends
Medicinova (MNOV) has reported Non-Current Assets for 16 consecutive years, with $14.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets fell 1.28% year-over-year to $14.6 million; the TTM figure through Dec 2025 stood at $58.7 million (down 1.45% YoY), while the FY2025 annual figure was $14.6 million, down 1.28% from the prior year.
- Non-Current Assets steadied at $14.6 million in Q4 2025 per MNOV's latest filing, from $14.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $25.2 million in Q3 2022 and bottomed at $14.6 million in Q4 2025.
- Historically, Non-Current Assets has averaged $15.5 million across 5 years, with a median of $15.1 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 63.24% — and 2023, when it plunged 40.02%.
- Medicinova's Non-Current Assets stood at $15.4 million in 2021, then decreased by 1.49% to $15.2 million in 2022, then fell by 0.48% to $15.1 million in 2023, then fell by 1.95% to $14.8 million in 2024, then retreated by 1.28% to $14.6 million in 2025.
- Business Quant data shows MNOV's Non-Current Assets at $14.6 million in Q4 2025, $14.7 million in Q3 2025, and $14.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Medicinova | 66.94 Mn | 66.94 Mn | 317,759.00 | 14.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.51 Mn |
| Dec 31, 2025 | 14.61 Mn |
| Sep 30, 2025 | 14.66 Mn |
| Jun 30, 2025 | 14.70 Mn |
| Mar 31, 2025 | 14.75 Mn |
| Dec 31, 2024 | 14.80 Mn |
| Sep 30, 2024 | 14.85 Mn |
| Jun 30, 2024 | 14.90 Mn |
| Mar 31, 2024 | 15.03 Mn |
| Dec 31, 2023 | 15.10 Mn |
| Sep 30, 2023 | 15.14 Mn |
| Jun 30, 2023 | 15.20 Mn |
| Mar 31, 2023 | 15.10 Mn |
| Dec 31, 2022 | 15.17 Mn |
| Sep 30, 2022 | 25.24 Mn |
| Jun 30, 2022 | 15.28 Mn |
| Mar 31, 2022 | 15.34 Mn |
| Dec 31, 2021 | 15.40 Mn |
| Sep 30, 2021 | 15.46 Mn |
| Jun 30, 2021 | 14.77 Mn |